Ambrx Biopharma Highlights Preclinical Data From Studies in Kidney, Prostate Cancer

Ambrx Biopharma Inc AMAM announced new preclinical data from ARX517 and ARX305 studies at the 2023 American Association for Cancer Research (AACR) Annual Meeting.
The stability of ARX517 was demonstrated in a non-human primate (monkey) study.
Pharmacokinetic measurements confirm the high stability of ARX517 in circulation with an extended half-life of 11 or 15 days.
The main metabolite of ARX517 cytotoxic linker payload, pAF-AS269, was barely measurable (0.2 ng/mL) in the serum in a repeat dosing study.
At the highest non-severely toxic dose (HNSTD), ARX517 serum exposure was greater than ARX517 exposure at a pharmacologically active dose in mice, showing a clear therapeutic index.
In an enzalutamide-sensitive mouse model of prostate cancer, ARX517 demonstrated anti-tumor activity. Further, the combination of 3 mg/kg ARX517 plus 10 mg/kg enzalutamide delivered an 86% reduction in tumor size.
In an enzalutamide-resistant prostate cancer model, three weekly doses of 3 mg/kg of ARX517 significantly inhibited tumor growth by 79% in a dose-dependent manner.
Ambrx is investigating ARX517 in the APEX-01 Phase 1 study in adult subjects and enrolling patients with advanced prostate cancer whose tumors have progressed following at least two FDA-approved treatments.
In a renal cell carcinoma (RCC, 786-OS3) xenograph model, ARX305 dose-dependently inhibited tumor growth and outperformed sunitinib.
In another RCC (Caki-1) xenograph model, weekly administration of ARX305 resulted in significant, dose-dependent, anti-tumor activity.
Pharmacokinetic studies of ARX305 in mice confirm the high ADC stability in circulation with a long terminal half-life of 16.5 days.
Price Action: AMAM shares are down 2.07% at $11.13 on the last check Wednesday.

Market News and Data brought to you by Benzinga APIs

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Ambrx Biopharma Highlights Preclinical Data From Studies in Kidney, Prostate Cancer

Comments